| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05cab2e54be5b03e7dd673d323c4ada0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554 |
| filingDate |
2018-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afcc8db544c0488b4dd9d066567a2f0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4de7da1cd9f8b438a8a823bc693d4f4c |
| publicationDate |
2020-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112019025636-A2 |
| titleOfInvention |
method for treating overactive bladder, method for increasing bladder smooth muscle relaxation, and pharmaceutical unit dosage composition |
| abstract |
the present disclosure relates to a method for treating overactive bladder which comprises administering orally to an individual who needs an amount of about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day. the present disclosure also relates to a pharmaceutical unit dosage composition comprising from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron for oral administration. |
| priorityDate |
2017-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |